A review of the 2026 Defense Health Agency testosterone screening policy for male service members alongside InCare’s safety guide covering TRT risks and monitoring.
On September 17, 2026, the Defense Health Agency announced new clinical guidance for testosterone deficiency screenings in male service members. Men aged 30 and older will receive this screening as part of periodic health assessments, upon military entry, or at annual physicals. Service members under 30 may be screened on request or when a medical provider identifies specific clinical indicators. Following this policy announcement, the 2026 InCare safety guide provides a timely review of the potential side effects and necessary clinical monitoring for testosterone replacement therapy.
The new military policy establishes a clear framework for when these conversations will happen. By incorporating these checks into periodic health assessments and annual physicals, the military aims to normalize discussions around endocrine health. For men under 30, the ability to request a screening provides an avenue for those experiencing symptoms to seek care. This creates a highly structured environment where identifying potential issues becomes a routine part of military service.
This policy shift significantly changes how the military approaches routine physical evaluations. The Defense Health Agency describes the new screening process as a structured symptom and risk factor assessment. Service members and clinicians will decide together on any treatment plan, with military medical professionals monitoring and adjusting it as needed. Secretary of War Pete Hegseth described the effort as restoring and optimizing natural capabilities rather than artificial enhancement.
The current screening policy specifically applies to male service members. The Defense Health Agency announcement stated that screening and treatment guidance for female service members would follow later. This upcoming guidance will be addressed in a separate companion document. Until then, the focus remains on standardizing how the military identifies potential hormone deficiencies in active duty men.
However, the new military screening policy faces significant opposition from medical professionals. The Endocrine Society directly criticized the Defense Health Agency approach in a public statement. The Society argues that the current evidence is insufficient for the population level screening of asymptomatic men. They strongly warn that screening men over 30 could yield many false positives while being expensive and time consuming.
The Endocrine Society’s critique highlights the tension between proactive screening and established medical guidelines. Their public statement underscores the difficulty of implementing a universal standard across a massive organization. The Society’s concerns reflect a broader medical consensus that emphasizes treating established clinical symptoms rather than testing asymptomatic populations. This fundamental disagreement will likely shape how individual military clinicians approach their daily patient evaluations.
The Endocrine Society also highlighted important demographic factors that complicate broad screening initiatives. The Society cited a 24.2 percent obesity rate among active service members as of 2023. They argued that obesity can frequently be associated with low total testosterone test results. This dynamic creates a risk of misinterpretation during routine physicals.
For individuals navigating these military assessments, it is critical to separate a screening from an actual diagnosis. The InCare educational guide emphasizes that testosterone replacement therapy should only be considered for a clinically confirmed deficiency. Diagnosis requires both compatible symptoms and consistently low testosterone levels on more than one blood test. These laboratory tests should ideally be taken in the morning to ensure accuracy.
The purpose of treatment must remain strictly medical. The InCare safety guide explicitly warns against using the therapy simply for normal aging. Treatment is also not recommended for the purpose of physical performance enhancement. This aligns closely with the stated military goals of focusing on established clinical needs.
Understanding the specific health risks of treatment requires a close look at clinical data. The InCare safety guide summarizes important cardiovascular findings from the 2023 TRAVERSE trial. Within the studied population, the trial found no increase in major adverse cardiovascular events when compared to a placebo. This finding helps clarify long standing debates about the safety of hormone replacement concerning major heart events.
Despite the lack of major adverse cardiovascular events, the trial did reveal other clinical risks. The InCare guide reports higher rates of specific complications in the testosterone group. Atrial fibrillation occurred in 3.5 percent of the testosterone group, compared to 2.4 percent in the placebo group. Acute kidney injury was observed in 2.3 percent of the treated patients, versus 1.5 percent for those on the placebo.
Additionally, pulmonary embolism was reported at 0.9 percent against 0.5 percent in the placebo group. The InCare article attributes these specific event figures to a Cleveland Clinic summary of the trial. The primary safety guide cautions that the reported TRAVERSE event differences do not automatically prove causation. Military medical professionals must weigh these statistics carefully against the individual health profile of the service member.
The combination of new screening policies and established safety literature mandates rigorous clinical oversight. The InCare guide lists several possible side effects of testosterone replacement therapy that require immediate attention. These physical changes can impact daily comfort and overall health. Reported side effects include potential acne, fluid retention, noticeable mood changes, and sleep disruptions.
Service members must report these symptoms to their medical provider promptly to allow for necessary treatment adjustments. Additionally, the guide reports that FDA labeling states testosterone products can increase blood pressure. Because of these potential side effects, routine periodic blood pressure checks are strongly advised. Monitoring these physical markers ensures that any negative changes are caught early in the treatment cycle.
Safe treatment relies heavily on strict baseline and follow up laboratory testing. The InCare guide recommends assessments that include checking testosterone levels and running a complete blood count. Elevated hematocrit is a known risk associated with treatment, making blood count monitoring essential. When prostate monitoring is chosen by the provider, specialized assessments become necessary.
These checkups may include a PSA test and a digital rectal examination. The InCare page attributes its suggested repeat prostate checks at three to twelve months to Endocrine Society guidance. The page does not provide a direct link to that original guidance document. Strict adherence to these follow up appointments helps mitigate the long term risks associated with continuous hormone replacement.
Fertility preservation is another critical element in any hormone therapy discussion. The InCare guide advises discussing fertility plans thoroughly before starting treatment. External testosterone administration can suppress sperm production significantly. The guide clearly cautions that testosterone replacement therapy is generally a poor fit for men planning to conceive soon.
Furthermore, the medication should never be treated as a reliable method of birth control. The Endocrine Society raised separate concerns regarding the fertility implications of the new military policy. The Defense Health Agency guideline includes a specific approach utilizing hCG to manage potential fertility concerns. Military clinicians often consider this approach for patients who wish to maintain reproductive capability during treatment.
However, the Endocrine Society argues that hCG can suppress FSH and reduce sperm production in some men with obesity induced hypogonadism. The Society provided further warnings about long term hormone management strategies. They stated that combined testosterone replacement therapy and hCG use for two or more years can delay the recovery of sperm and hormone production. Service members must navigate these complex military hormone protocols carefully with their providers to protect their future health.
Proper clinical evaluation remains the most important step in mitigating these risks. Before committing to treatment, veterans must undergo a comprehensive symptom and hormone evaluation to confirm any true deficiency. A structured clinical approach helps prevent unnecessary exposure to long term side effects. Similar to navigating dietary supplements safely, making informed choices about hormone replacement requires understanding the rigorous clinical monitoring that must accompany it.
As routine hormone screenings become standard practice across military installations, how will the Department of Defense adjust its clinical protocols to manage the long term monitoring and fertility risks associated with widespread testosterone therapy?
Follow BattleVet for practical guidance on military and veteran health, strength, recovery, testosterone, sleep and healthy aging. Stay connected for new articles, research backed insights and clear information to help you stay capable for the years ahead.
A multi-year study links modest blood sugar increases to declining erectile function, reinforcing the value of metabolic health alongside hormone evaluation.
Learn how to navigate VA community care referral delays, access standards, and individual eligibility following the October 2026 Colorado Springs roundtable.
A controlled study found nighttime heat disrupted sleep and altered stress markers. Learn how this impacts military recovery protocols and veteran health.
Build better habits around strength, recovery, sleep, hormones and healthy aging with practical guidance for active military personnel and veterans.
Explore BattleVet